- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06187506
Disitamab Vedotin Combined With BCG Therapy in HER2-expressing High-risk Non-muscle Invasive Bladder Cancer
A Prospective, Open, Single-center Clinical Study of Disitamab Vedotin Combined With BCG Therapy in HER2-expressing High-risk Non-muscle Invasive Bladder Cancer
Study Overview
Status
Intervention / Treatment
Detailed Description
The study will include patients with very high risk NMIBC with HER2 expression (IHC 1+/2+/3+) who refuse to undergo cystectomy or do not meet the requirements for cystectomy. Reasons for unsuitability or refusal of cystectomy will be documented on an electronic case report form (eCRF).
Subjects will receive 6 months of Disitamab Vedotin therapy and at least 1 year of BCG therapy. EFS(Event free survival) and CR(Complete response) rates will be evaluated after treatment by cystoscopy, pathologic histology, urine cytology, laboratory tests, and imaging. Cystoscopy and urine cytology every three months for two years, and radiography every six months. Cystoscopy and urine cytology were done every six months and radiography once a year after two years.
Study Type
Enrollment (Estimated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Dingwei Ye, Doctor
- Phone Number: 64175590-82800
- Email: dwyeli@163.com
Study Contact Backup
- Name: Yijun Shen, Doctor
- Phone Number: 64175590-82800
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Age≥18 years;
- Histologically confirmed non-muscle-invasive urothelial cell carcinoma (UCC) of the bladder; A.Histopathology: any variant of UCC, The presence of any lymphovascular infiltration (LVI) was considered evidence of high risk. B. Confined to the mucosal (Ta, Tis) and lamina propria layers (T1) of the bladder. In addition, subjects had all visible tumors removed as completely as possible prior to the first dose of study drug and documented at baseline cystoscopy. C. CIS(Carcinoma in situ) does not require complete resection, but coexisting papillary carcinoma must be removed as completely as possible prior to enrollment and documented at baseline cystoscopy. Negative urine cytology results against malignant tumor cells are not required.
- Presence of HER2 expression (IHC 1+/2+/3+) by IHC in our pathology department;
- VHR(Very high risk) NMIBC, defined as having at least 1 of the following: Multiple and/or large (greater than [>] 3 centimeters [cm]) T1, (HG/G3) tumors; T1, (HG/G3) tumor with concurrent CIS; T1, G3 with CIS in prostatic urethra; Micropapillary variant of non-muscle invasive urothelial carcinoma;
- Received first dose of medication ≤ 12 weeks from first TURBT;
- Refusal or unsuitability for radical cystectomy;
- Eastern Cooperative Oncology Group (ECOG) performance status of less than or equal to (</=) 1;
- Adequate hematologic and end-organ function, Creatinine clearance >/=30 milliliters per minute (mL/min) (calculated using the Cockcroft-Gault formula);
- Subjects (or their legal representatives) must sign an informed consent form (ICF);
- Females of childbearing potential must have a negative pregnancy test result (beta-hCG) (urine or serum) within 7 days prior to the first dose of study drug.
Exclusion Criteria:
- Evidence of locally advanced, metastatic, muscle-invasive, and/or extravesical bladder cancer;
- Upper urinary tract urothelial carcinoma(UTIC), except 2 years without recurrence after previous radical UTUC;
- Histopathologic examination reveals any small cell component of the bladder, simple adenocarcinoma, simple squamous cell carcinoma or simple squamous CIS;
- Previously received other anti-HER-2 therapy;
- Active malignancy outside of the disease being treated by the study (i.e., disease progression or need for change in therapy within the past 24 months);Only the following special cases are allowed: a. Skin cancer treated within the last 24 months and completely cured; b. Adequately treated lobular carcinoma in situ (LCIS) and ductal CIS; c. History of localized breast cancer and receiving anti-hormonal drugs or history of localized prostate cancer (N0M0) and receiving androgen blockade therapy.
- History of uncontrolled cardiovascular disease, Included: 1) presence of any of the following in the past 3 months: unstable angina, myocardial infarction, ventricular fibrillation, torsional ventricular tachycardia, cardiac arrest or known congestive New York Heart Association class III-IV heart failure, cerebrovascular accident, or transient ischemic attack. 2) Prolonged QTc intervals confirmed by ECG evaluation during screening(Fridericia; QTc>480 ms). 3) Pulmonary embolism or other venous thromboembolism within the past 2 months.
- Pregnant or lactating women;
- Known infection with human immunodeficiency virus (HIV), unless the subject has been on stable antiretroviral therapy for the past 6 months or longer and has not had an opportunistic infection in the past 6 months and has had a CD4 count >350 in the past 6 months;
- Evidence of active hepatitis B or C infection (e.g., subjects with hepatitis B who have a history of hepatitis C but have a normal polymerase chain reaction test result for hepatitis C virus and who are positive for antibodies to hepatitis B surface antigen may be enrolled in the study);
- Have not recovered from toxic effects of previous anticancer therapy (except for toxic effects of no clinical significance, such as alopecia, skin discoloration, neuropathy and hearing impairment).
- Delayed wound healing, defined as skin/decubitus ulcers, chronic leg ulcers, known gastric ulcers, or non-healing incisions;
- Major surgery within 4 weeks prior to day 1 of cycle 1 (TURBT not considered major surgery);
- Other patients assessed by the investigator to be unsuitable for participation in this study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: RC48+BCG
Disitamab Vedotin (2.0 mg/kg, administered intravenously every three weeks); BCG therapy: Induction therapy, i.e., intravesical therapy once a week for 6 weeks.
maintenance therapy, i.e., one course of maintenance therapy at three, six and twelve months after surgery, each course once a week for 3 weeks.
|
2.0 mg/kg, administered intravenously every three weeks
Other Names:
Induction therapy, i.e., intravesical therapy once a week for 6 weeks.
maintenance therapy, i.e., one course of maintenance therapy at three, six and twelve months after surgery, each course once a week for 3 weeks.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of Participants With CR as Assessed by the Investigator according to Cystoscopy and Urine Cytology at Month 3
Time Frame: up to 3 months
|
CR at the 3-month disease assessment, evaluated by both cystoscopy and cytology.
|
up to 3 months
|
Event-Free Survival (EFS) rate, as Assessed according to Cystoscopy and Urine Cytology
Time Frame: up to 6 months
|
Percentage of Participants With Event-Free Survival (EFS), as assessed according to Cystoscopy and Urine Cytology ( patients who are alive and free of persistent/recurrent high-grade NMIBC.)
|
up to 6 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of Participants With CR as Assessed by the Investigator according to Cystoscopy and Urine Cytology at Month 6, 12
Time Frame: up to 12 months from the date of randomization as assessed by the investigator according to cystoscopic assessment and urine cytology
|
CR at the 6, 12-month disease assessment, evaluated by both cystoscopy and cytology.
|
up to 12 months from the date of randomization as assessed by the investigator according to cystoscopic assessment and urine cytology
|
Duration of CR will be defined for participants with a CR as the time from the first occurrence of a documented complete response to recurrence of high-grade NMIBC or death from any cause.
Time Frame: From first occurence of a documented CR until the time of recurrence of NMIBC or death from any cause, whichever came first, assessed up to 24 months
|
Duration of CR will be defined for participants with a CR as the time from the first occurrence of a documented complete response to recurrence of high-grade NMIBC or death from any cause.
|
From first occurence of a documented CR until the time of recurrence of NMIBC or death from any cause, whichever came first, assessed up to 24 months
|
Percentage of Participants With Event-Free Survival (EFS), as Assessed according to Cystoscopy and Urine Cytology
Time Frame: up to 24 months
|
EFS rate at 12, 24 months, defined as the proportion of patients who are alive and free of persistent/recurrent high-grade NMIBC.
|
up to 24 months
|
Progression-Free Survival (PFS), as Assessed according to Cystoscopy and Urine Cytology
Time Frame: Time from date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 60 months
|
PFS, defined as the time from the first study treatment to the first occurrence of progression to muscle-invasive disease based on cystoscopy and urine cytology or death from any cause.
|
Time from date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 60 months
|
Overall Survival
Time Frame: Time from date of randomization to death from any cause, assessed up to 60 months
|
defined as the time from first study treatment to death from any cause
|
Time from date of randomization to death from any cause, assessed up to 60 months
|
Percentage of Participants With Adverse Events
Time Frame: up to 24 months
|
Percentage of participants with at least one adverse event during the study
|
up to 24 months
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Dingwei Ye, Fudan University
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neoplasms by Histologic Type
- Neoplasms
- Urologic Neoplasms
- Urogenital Neoplasms
- Neoplasms by Site
- Urologic Diseases
- Carcinoma
- Neoplasms, Glandular and Epithelial
- Urinary Bladder Diseases
- Female Urogenital Diseases
- Female Urogenital Diseases and Pregnancy Complications
- Urogenital Diseases
- Male Urogenital Diseases
- Urinary Bladder Neoplasms
- Non-Muscle Invasive Bladder Neoplasms
- Physiological Effects of Drugs
- Immunologic Factors
- Adjuvants, Immunologic
- Immunoconjugates
- BCG Vaccine
- Disitamab vedotin
Other Study ID Numbers
- RC48C066
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Non-muscle Invasive Bladder Cancer
-
Aura BiosciencesRecruitingMuscle-Invasive Bladder Carcinoma | Non-muscle-invasive Bladder CancerUnited States
-
Nucleix Ltd.CompletedNon Muscle Invasive Bladder Cancer | Non-Muscle Invasive Bladder Urothelial CarcinomaUnited States
-
University of Roma La SapienzaNot yet recruitingNon-muscle-invasive Bladder Cancer | Non-Muscle Invasive Bladder Urothelial Carcinoma | High Risk Non-Muscle Invasive Bladder Urothelial Carcinoma
-
AstraZenecaHospital Israelita Albert EinsteinRecruitingUrothelial Carcinoma | Muscle-invasive Bladder Cancer | Non Muscle Invasive Bladder CancerBrazil
-
Huazhong University of Science and TechnologyRecruitingBladder Cancer | Non-Muscle-Invasive Bladder CancerChina
-
Jiangsu Simcere Pharmaceutical Co., Ltd.Shanghai Xianxiang Medical Technology Co., Ltd.RecruitingNon-Muscle-Invasive Bladder Cancer (NMIBC)China
-
RenJi HospitalBeiGene; RemeGen Co., Ltd.RecruitingHER2 | Non-Muscle Invasive Bladder CancerChina
-
White River Junction Veterans Affairs Medical CenterMedical University of South Carolina; National Cancer Institute (NCI); University...RecruitingNon-muscle-invasive Bladder CancerUnited States
-
Al-Azhar UniversityRecruiting
-
ECOG-ACRIN Cancer Research GroupNational Cancer Institute (NCI)Recruiting
Clinical Trials on Disitamab vedotin
-
Tianjin Medical University Second HospitalRecruitingHer2 Overexpressing High-Risk Non-Muscle Invasive Bladder Urothelial CarcinomaChina
-
RemeGen Co., Ltd.Recruiting
-
RemeGen Co., Ltd.Not yet recruitingHigh-risk Non-muscle Invasive Bladder CancerChina
-
Peking University Cancer Hospital & InstituteNot yet recruitingMetastatic Castration-resistant Prostate Cancer
-
Seagen Inc.RecruitingCarcinoma, Non-Small-Cell Lung | Ovarian Neoplasms | Endometrial Neoplasms | Carcinoma, Squamous Cell of Head and NeckUnited States, Australia, Canada
-
Wuhan Union Hospital, ChinaRecruitingBreast Cancer | Neoadjuvant TherapyChina
-
The Affiliated Nanjing Drum Tower Hospital of Nanjing...Not yet recruiting
-
Qilu Hospital of Shandong UniversityNot yet recruiting
-
Wuhan Union Hospital, ChinaNot yet recruitingUrothelial Carcinoma